Indication: Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer
5 questions · 5 sources
Indication
What is Enhertu approved for in HER2-low breast cancer?
Testing
How are patients selected for Enhertu in HER2-low breast cancer?
On the page, select: HER2-low or HER2-ultralow unresectable or metastatic breast cancer
What does HER2-ultralow mean for Enhertu eligibility?
On the page, select: HER2-low or HER2-ultralow unresectable or metastatic breast cancer